Monash Fragment Platform

Our Fragment Based Drug Design platform (MFP) provides academic and commercial researchers with access to fragment-based drug discovery technologies for their therapeutic targets. The facilities are located at the Monash Institute of Pharmaceutical Sciences – Australia’s largest and most successful pharmaceutical institute. FBDD screening uses our high-quality, in-house fragment library designed to maximise chemical space coverage and enable rapid hit optimisation. Screening cascades are
tailored for each target and can be performed using a variety of techniques including NMR spectroscopy and our surface plasmon resonance (SPR) facility.